Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer

US11572405B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Michael Carleton · Princeton, US
• David FELTQUATE · Montgomery, US
• Olivier De Henau · Brussels, BE
• Timothy P. Reilly · New Hope, US
• Tian Chen · Evanston, US
• Ye FENG · Princeton, US
• Shu-Pang Ben HUANG · Newtown, US
• Ming Zhou · Coppell, US
• Ramachandran SURESH · Hoffman, US

Key dates

• Filing date: Jan 11, 2019
• Grant date: Feb 7, 2023
• Expiry date: Mar 19, 2039

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody.